临床心身疾病杂志
臨床心身疾病雜誌
림상심신질병잡지
JOURNAL OF CLINICAL PSYCHOSOMATIC DISEASES
2015年
4期
42-44
,共3页
精神分裂症%急性激越症状%齐拉西酮%氟哌啶醇%肌内注射%阳性与阴性症状量表%兴奋因子
精神分裂癥%急性激越癥狀%齊拉西酮%氟哌啶醇%肌內註射%暘性與陰性癥狀量錶%興奮因子
정신분렬증%급성격월증상%제랍서동%불고정순%기내주사%양성여음성증상량표%흥강인자
Schizophrenia%acutely agitated symptom%ziprasidone%haloperidol%intramuscular injection%PANSS%excitatory factor
目的：探讨肌内注射齐拉西酮注射液治疗精神分裂症患者急性激越症状的疗效和安全性。方法将80例伴急性激越症状的精神分裂症患者随机分为两组，实验组肌内注射齐拉西酮注射液治疗，对照组肌内注射氟哌啶醇注射液治疗，观察3d。于治疗前后采用阳性与阴性症状量表总分及兴奋因子分评定临床疗效，副反应量表评定不良反应。结果治疗第1d起两组阳性与阴性症状量表总分及兴奋因子评分均较治疗前显著下降（P＜0．01），治疗各时点两组评分比较差异均无显著性（ P＞0．05）；治疗第3 d后实验组急性激越症状显效率67．5％、总有效率92．5％，对照组分别为72．5％、95．0％，两组比较差异无显著性（χ2＝0．24、0．21，P＞0．05）。两组不良反应程度较轻微，但研究组不良反应发生率显著低于对照组（χ2＝4．11，P＜0．05）。结论肌内注射齐拉西酮注射液能够快速有效控制精神分裂症急性激越症状，疗效与氟哌啶醇相当，但安全性更高，有利于患者的连续性治疗。
目的：探討肌內註射齊拉西酮註射液治療精神分裂癥患者急性激越癥狀的療效和安全性。方法將80例伴急性激越癥狀的精神分裂癥患者隨機分為兩組，實驗組肌內註射齊拉西酮註射液治療，對照組肌內註射氟哌啶醇註射液治療，觀察3d。于治療前後採用暘性與陰性癥狀量錶總分及興奮因子分評定臨床療效，副反應量錶評定不良反應。結果治療第1d起兩組暘性與陰性癥狀量錶總分及興奮因子評分均較治療前顯著下降（P＜0．01），治療各時點兩組評分比較差異均無顯著性（ P＞0．05）；治療第3 d後實驗組急性激越癥狀顯效率67．5％、總有效率92．5％，對照組分彆為72．5％、95．0％，兩組比較差異無顯著性（χ2＝0．24、0．21，P＞0．05）。兩組不良反應程度較輕微，但研究組不良反應髮生率顯著低于對照組（χ2＝4．11，P＜0．05）。結論肌內註射齊拉西酮註射液能夠快速有效控製精神分裂癥急性激越癥狀，療效與氟哌啶醇相噹，但安全性更高，有利于患者的連續性治療。
목적：탐토기내주사제랍서동주사액치료정신분렬증환자급성격월증상적료효화안전성。방법장80례반급성격월증상적정신분렬증환자수궤분위량조，실험조기내주사제랍서동주사액치료，대조조기내주사불고정순주사액치료，관찰3d。우치료전후채용양성여음성증상량표총분급흥강인자분평정림상료효，부반응량표평정불량반응。결과치료제1d기량조양성여음성증상량표총분급흥강인자평분균교치료전현저하강（P＜0．01），치료각시점량조평분비교차이균무현저성（ P＞0．05）；치료제3 d후실험조급성격월증상현효솔67．5％、총유효솔92．5％，대조조분별위72．5％、95．0％，량조비교차이무현저성（χ2＝0．24、0．21，P＞0．05）。량조불량반응정도교경미，단연구조불량반응발생솔현저저우대조조（χ2＝4．11，P＜0．05）。결론기내주사제랍서동주사액능구쾌속유효공제정신분렬증급성격월증상，료효여불고정순상당，단안전성경고，유리우환자적련속성치료。
Objective To explore the efficacy and safety of ziprasidone intramuscular injection for acutely agitated symptoms of schizophrenia .Methods Eighty schizophrenics with acutely agitated symptoms were randomly divided into two groups ,experimental group was treated with intramuscular ziprasidone and con‐trol group with haloperidol for 3 days .Before and after treatment efficacies were assessed with the total and excitatory factor score of the Positive and Negative Syndrome Scale (PANSS ) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results Since the 1st day of treatment the total and excitatory factor score of the PANSS of both groups lowered more significantly compared with pre‐treatment (P<0 .01) ,there were no significant group differences in each time‐point score (P>0 .05);af‐ter the 3rd day treatment obvious and total effective rate were respectively 67 .5% and 92 .5% in experimen‐tal and 72 .5% and 95 .0% in control group ,which showed no significant group differences (χ2 = 0 .24 , 0 .21 ;P>0 .05) .Adverse reactions of both groups were mild ,but their incidence was significantly lower in research than in control group (χ2 = 4 .11 ,P< 0 .05) .Conclusion Intramuscular ziprasidone could quickly and effectively control acutely agitated symptoms of schizophrenia ,its efficacy is equivalent to hal‐operidol ,but its safety higher ,and it beneficial to patients’ continuous treatment .
